SOVREMENNAYa ANTIGIPERTENZIVNAYa TERAPIYa: FOKUS NA LERKANIDIPIN


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article considers the potentials for the use of a relatively new representative of calcium slow channel blockers, lercanidipine, in different variants of arterial hypertension. These data strongly suggest that it may be recommended for the wide use as an antihypertensive agent. The drug combines stable antihypertensive effect and organoprotective action, while well tolerated. The use of lercanidipine in the fixed combinations of antihypertensive drugs for the treatment of patients with renal diseases, rheumatic diseases, and diabetes is especially promising.

Full Text

Restricted Access

About the authors

A. P Rebrov

Email: rebrov_ap@sgmu.ru

E. V Grigor'eva

References

  1. Mancia G., Fagard R., Narkiewicz K., et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. TheTask Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 2013; 31: 1281-357.
  2. Peters M.J., Symmons D.P., McCarey D., et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann. Rheum. Dis. 2010; 69(2): 325-31.
  3. Avina-Zubieta J.A., Choi H.K., Sadatsafavi M., et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008; 59: 1690-97.
  4. Dougados M., Soubrier M., Antunez A., et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann. Rheum. Dis. 2014; 73(1): 62-8.
  5. Bartels C.M., Johnson H., Voelker K., et al. Impact of rheumatoid arthritis on receiving a diagnosis of hypertension among patients with regular primary care. Arthritis Care Res. (Hoboken). 2014. Feb 28. doi: 10.1002/acr.22302. [Epub ahead of print].
  6. Protogerou A.D., Panagiotakos D.B., Zampeli E., et al. Arterial hypertension assessed «out-of-office» in a contemporary cohort of rheumatoid arthritis patients free of cardiovascular disease is characterized by high prevalence, low awareness, poor control and increased vascular damage-associated «white coa» phenomenon. Arthritis Res. Ther. 2013; 15(5): R142.
  7. Manavathongchai S., Bian A., Rho Y.H., et al. Inflammation and hypertension in rheumatoid arthritis. J. Rheumatol. 2013; 40(11): 1806-11.
  8. Primdahl J., Clausen J., Horslev-Petersen K. Results from systematic screening for cardiovascular risk in outpatients with rheumatoid arthritis in accordance with the EULAR recommendations. Ann. Rheum. Dis. 2013; 72(11): 1771-76.
  9. Marcos Sanchez F., Santurino Martin J.A., Barbudo Ousset M.M., Reinoso Cobo D. [The loss of the efficacy of captopril due to indomethacin]. Aten. Primaria. 1993; 11(3): 155. ЛИТЕРАТУРА
  10. Herbette L.G., Vecchiarelli M., Leonardi A. Lercanidipine: short plasma half-life, long duration of action. J. Cardiovascul. Pharmacol. 1997; 29 (suppl 1); S19-S24.
  11. Circo A. Active dose findings for lercanidipine in double-blind, placebo-controlled design in patients with mild to moderate essential hypertension. J. Cardiovascul. Pharmacol. 1997; 29: S21-25.
  12. Angelico P., Guameri L., Leonardi A., Testa R. Vascular-selective effect of lercanidipine and other 1,4-dihydropyri-dines in insolated rabbit tissues. J. Pharm. Pharmacol. 1999; 51: 709-14.
  13. Bang L.M., Chapman T.M., Goa K.L. Lercanidipine - a review of its efficacy management of hypertension. Drugs 2003; 22: 2449-72.
  14. Минушкина А.О. Лечение артериальной гипертонии у больных с хронической болезнью почек: фиксированная комбинация лерканидипина и эналаприла. Кардиология 2013; 12: 64-9.
  15. Kukes V.G., Ostroumova O.D., Starodubtsev A.K. Calcium antagonists: modern aspect of cardiology. Consilium medicum. 2006; 8(11): 113-17.
  16. Стрюк Р.И. Место лерканидипина в лечении сердечно-сосудистых заболеваний. Кардиология. 2013; 4100-103.
  17. Robles N.R., Romero B., de Vinuesa E.G. Treatment of proteinuria with lercanidipine associated with rennin-angiotensin axis-blocking drugs. Ren. Fail. 2010; 32: 192-97.
  18. Topal C., Erkoc R., Sayarlioglu H. Comparative effects of carvedilol and lercanidipine on ultrafiltration and solute transport in CAPD patients. Ren. Fail. 2010; 31: 446-51.
  19. Кукес В.Г. Клиническая фармакология. М: ГЭОТАР-Медиа, 2008.
  20. Мамедов М.Н., Ковригина М.Н., Тогузова З.А. Рациональный подход в лечении артериальной гипертонии у больных с высоким сердечно-сосудистым риском и метаболическими нарушениями. Кардиология. 2013; 2: 85-90.
  21. Фомин В.В., Свистунов А.В. Лерканидипин: эволюция дигидропиридиновых антагонистов кальция продолжается. Кардиология. 2012; 11: 75-9.
  22. Минушкина Л.О., Иосава И.К. Лекарнидипин в лечении артериальной гипертензии. Кардиология. 2012; 12: 70-4.
  23. Sabbatini M., Tomassoni D., Amenta F. Influence of treatment with Ca2+-antagonists on cerebral vasculature of spontaneously hypertensive rats. Mech. Ageing Dev. 2001; 122: 795-809.
  24. Остроумова О.Д., Максимов М.Л., Копченов И.И. Антагонист кальция третьего поколения лерканидипин: новые возможности в лечении артериальной гипертензии. Рациональная фармакотерапия в кардиологии. 2013; 9(1 ).
  25. Tisaire-Sanchez J., Roma J., Camacho-Azcargorta I., et al. Assessment of cognitive function in patients with essential hypertension treated with lercanidipine. Vasc. Health Risk Manag. 2006; 2: 491-98.
  26. Omboni S., Zanchetti A. for the Multicenter Study Investigators. Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. J. Hypertens. 1998; 16: 1831-38.
  27. Repine C.J., Handberg E.M., Cooper-Dehoff R.M., et al. A calcium antagonists a non-calcium antagonists hypertension treatment strategy for patients with coronary artery disease. JAMA. 2003; 290: 2805-16.
  28. Lund-Johansen P., Stranden E., Helberg S., et al. Quantification of legoedema in postmenopausal hypertensive patients treated with lercanidipine oramlodipine. J. Hypertens. 2003; 21: 1003-10.
  29. Максимов М.Л., Стародубцев А.К., Светлый И.И. Эффективность блокаторов медленных кальциевых каналов в лечении артериальной гипертензии. РМЖ. 2005; 14: 132-37.
  30. Hansson L., Zanchetti A., Carruters S., et al. Effect of intensive blood pressure lowering and low-dose patients with hypertension principal results of the hypertension optimal treatment (HOT) randomized trial. Lancet. 1998; 351: 1755-62.
  31. Bangalore S., Kamalakkannan G., Parkar S., Messerli F.H. Fixed-Dose Combinations Improve Medication Compliance: A Meta-Analysis. Am. J. Med. 2007; 120: 713-19.
  32. Dahlot B., Sever P.S., Poulter N.R. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumenthiazide as required, in Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentral randomized controlled trial. Lancet. 2005; 366: 895-906.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies